EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expanding the MYCN Variant Spectrum in Feingold Syndrome Type 1: A Novel N-Terminal Missense Variant Segregating in an Affected Family

Francisco Javier Mérida De la Torre iD, Javier Porta Pelayo, Inmaculada Ortiz-Martín

Genes · 05.05.2026 · 17 (5) · 552

DOI: 10.3390/genes17050552 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, online erschienen am 05.05.2026. Verfasst von Francisco Javier Mérida De la Torre und 2 weiteren Autor:innen. Beteiligte Einrichtung: Genetics Laboratory, Hospital Regional Universitario, 29011 Málaga, Spain. Hauptthemen laut MEDLINE: Intellectual Disability, Microcephaly, Mutation, Missense, N-Myc Proto-Oncogene Protein. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study reports a previously unreported heterozygous MYCN missense variant, c.454G>A (p.Ala152Thr), identified in a child and two affected relatives, with clinical findings consistent with Feingold syndrome type 1, an autosomal dominant developmental disorder most commonly caused by loss-of-function variants in MYCN. The proband presented with a cleft palate, craniofacial dysmorphism, feeding difficulties, hypotonia, and characteristic digital anomalies. Similar features were observed in the father and sibling. Clinical exome sequencing revealed the novel MYCN variant, which was confirmed by Sanger sequencing and demonstrated co-segregation with the phenotype. Although most pathogenic MYCN variants leading to FS1 truncate the protein, this missense change lies within the N-terminal transactivation domain, a region involved in transcriptional regulation and protein stability. The physicochemical alteration introduced at residue Ala152 may plausibly affect MYCN function, consistent with haploinsufficiency as the established disease mechanism. According to the 2024 ACGS Best Practice Guidelines, the variant was classified as a variant of uncertain significance leaning toward pathogenicity. This report expands the mutational spectrum of MYCN, supports the potential clinical relevance of N-terminal missense variation in MYCN, and highlights intrafamilial phenotypic variability in FS1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intellectual DisabilityMicrocephalyMutation, MissenseN-Myc Proto-Oncogene ProteinTracheoesophageal FistulaChild, PreschoolFemaleHumansMalePedigreePhenotypeEyelidsLimb Deformities, Congenital

Stichwörter der Autor:innen

Feingold Syndrome Type IMYCNcase reportcongenital abnormalitiesdevelopmental disorder

Substanzen

MYCN protein, humanN-Myc Proto-Oncogene Protein

Autor:innen und Institutionen

  • Genetics Laboratory, Hospital Regional Universitario, 29011 Málaga, Spain.
  • Genologica by Health in Code, 29016 Málaga, Spain.

ORCID-Profile: Francisco Javier Mérida De la Torre

Zitieren

APA

Javier Mérida De la Torre, F., Porta Pelayo, J., & Ortiz-Martín, I. (2026). Expanding the MYCN Variant Spectrum in Feingold Syndrome Type 1: A Novel N-Terminal Missense Variant Segregating in an Affected Family. Genes, 17(5), 552. https://doi.org/10.3390/genes17050552

Vancouver

Javier Mérida De la Torre F, Porta Pelayo J, Ortiz-Martín I. Expanding the MYCN Variant Spectrum in Feingold Syndrome Type 1: A Novel N-Terminal Missense Variant Segregating in an Affected Family. Genes. 2026;17(5):552. doi:10.3390/genes17050552

BibTeX
@article{JavierMridaDelaTorre2026,
  author = {Javier Mérida De la Torre, Francisco and Porta Pelayo, Javier and Ortiz-Martín, Inmaculada},
  title = {Expanding the MYCN Variant Spectrum in Feingold Syndrome Type 1: A Novel N-Terminal Missense Variant Segregating in an Affected Family},
  journal = {Genes},
  year = {2026},
  volume = {17},
  number = {5},
  pages = {552},
  doi = {10.3390/genes17050552}
}
Kostenlos starten →